Clinical Drug Investigation

, Volume 39, Issue 2, pp 221–229 | Cite as

Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU

  • Sohita DhillonEmail author


Neratinib (Nerlynx®) is an oral, irreversible pan-human epidermal growth factor receptor (HER) tyrosine kinase inhibitor of HER1, HER2 and HER4. Neratinib therapy for 12 months significantly reduced the risk of invasive disease recurrence or death relative to placebo at both 2 and 5 years post-randomization in the pivotal ExteNET trial in women with early-stage HER2-positive breast cancer who had completed adjuvant trastuzumab. Subgroup analyses showed that patients with hormone receptor (HRc)-positive disease derived greater benefit with neratinib than patients with HRc-negative disease, and patients who initiated neratinib within 1 year of completing trastuzumab had better outcomes than those who started treatment 1–2 years after trastuzumab. This led to the approval of neratinib in the EU as extended adjuvant therapy for patients with early-stage HRc-positive, HER2-positive breast cancer and who are less than 1 year from completion of prior adjuvant trastuzumab-based therapy. It is the first agent of its class to be approved in the EU in this setting. As with other tyrosine kinase inhibitors, diarrhoea, which was manageable with antidiarrhoeal prophylaxis and/or dose modifications, was the most common any-grade or grade ≥ 3 treatment-emergent adverse event with neratinib. Thus, current evidence indicates that neratinib provides a valuable option to reduce the risk of recurrence in this setting and has been included in the updated ESMO patient guide as an extended adjuvant therapy for some patients.



The manuscript was reviewed by: J. Jeong, Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea; F. Montemurro, Multidiscliplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Cadiolo, Italy; F. Muggia, NYU Cancer Institute, Kaplan Cancer Center, New York University Medical Center, New York, NY, USA. During the peer review process, the manufacturer of neratinib was offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflicts of interest

S. Dhillon is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.


  1. 1.
    Mitri Z, Constantine T, O’Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;2012:743193.Google Scholar
  2. 2.
    Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008;65(10):1566–84.CrossRefGoogle Scholar
  3. 3.
    Lambertini M, Ponde NF, Solinas C, et al. Adjuvant trastuzumab: a 10-year overview of its benefit. Expert Rev Anticancer Ther. 2017;17(1):61–74.CrossRefGoogle Scholar
  4. 4.
    Kourie HR, El Rassy E, Clatot F, et al. Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib. Onco Targets Ther. 2017;10:3363–72.CrossRefGoogle Scholar
  5. 5.
    Puma Biotechnology. Nerlynx (neratinib): US prescribing Information. 2017. Accessed 4 Dec 2018.
  6. 6.
    European Medicines Agency. Nerlynx (neratinib): summary of product characteristics. 2018. Accessed 4 Dec 2018.
  7. 7.
    Puma Biotechnology I. European Commission grants Marketing Authorisation for Puma Biotechnology’s NERLYNX® (neratinib) for extended adjuvant treatment of hormone receptor positive HER2-positive early stage breast cancer [media release]. 4 Sept 2018.
  8. 8.
    Rabindran SK, Discafani CM, Rosfjord EC, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004;64(11):3958–65.CrossRefGoogle Scholar
  9. 9.
    Canonici A, Gijsen M, Mullooly M, et al. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 2013;4(10):1592–605.CrossRefGoogle Scholar
  10. 10.
    Luque-Cabal M, Garcia-Teijido P, Fernandez-Perez Y, et al. Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it. Clin Med Insights Oncol. 2016;10(Suppl 1):21–30.Google Scholar
  11. 11.
    Feldinger K, Kong A. Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press). 2015;7:147–62.Google Scholar
  12. 12.
    Giuliano M, Trivedi MV, Schiff R. Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care. 2013;8(4):256–62.CrossRefGoogle Scholar
  13. 13.
    European Medicines Agency. Nerlynx (neratinib): assessment report. 2018. Accessed 4 Dec 2018.
  14. 14.
    Sudhan DR, Schwarz LJ, Guerrero-Zotano A, et al. Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains completerResponses of ER(+)/HER2(+) breast cancers: implications to the ExteNET trial. Clin Cancer Res. 2018.Google Scholar
  15. 15.
    Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367–77.CrossRefGoogle Scholar
  16. 16.
    Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1688–700.CrossRefGoogle Scholar
  17. 17.
    Gnant M, Martin M, Holmes FA, et al. Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2 + early stage breast cancer: subgroup analyses from the phase III ExteNET trial [abstract no. 603 plus poster]. In: San Antonio Breast Cancer Symposium 2018.
  18. 18.
    Hurvitz S, Chan A, Iannotti N, et al. Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2 + early-stage breast cancer: the CONTROL trial [abstract no. P3-14-01 plus poster]. Cancer Res. 2017;78(4 Suppl).
  19. 19.
    Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8–30.CrossRefGoogle Scholar
  20. 20.
    European Medicines Agency. Perjeta (pertuzumab): summary of product characteristics. 2018. Accessed 4 Dec 2018.
  21. 21.
    Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol. 2008;19(6):1090–6.CrossRefGoogle Scholar
  22. 22.
    Strasser-Weippl K, Horick N, Smith IE, et al. Long-term hazard of recurrence in HER2 + breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res. 2015;17:56.CrossRefGoogle Scholar
  23. 23.
    Bossi P, Antonuzzo A, Cherny NI, et al. Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv126–42.CrossRefGoogle Scholar
  24. 24.
    Ustaris F, Saura C, Palma JD, et al. Effective management and prevention of neratinib-induced diarrhea. Am J Hematol Oncol. 2015;11(11):13–22.Google Scholar
  25. 25.
    Chavez-MacGregor M, Mittendorf EA. Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions. Lancet Oncol. 2017;18(12):1568–9.CrossRefGoogle Scholar
  26. 26.
    ESMO. Breast Cancer: an ESMO guide for patients. 2018. Accessed 4 Dec 2018.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations